Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation (ADJUVANT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01405079

Recruitment Status : Unknown

Verified February 2020 by Yi-Long Wu, Guangdong Association of Clinical Trials.
Recruitment status was: Active, not recruiting

First Posted : July 29, 2011

Last Update Posted : February 18, 2020

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

Guangdong Provincial People's Hospital

First Affiliated Hospital, Sun Yat-Sen University

Sun Yat-sen University

Jilin Provincial Tumor Hospital

Liaoning Tumor Hospital & Institute

First Hospital of China Medical University

Chinese PLA General Hospital

Peking Union Medical College Hospital

Peking University People's Hospital

Beijing Chest Hospital

309th Hospital of Chinese People's Liberation Army

Peking University Cancer Hospital & Institute

Peking University First Hospital

Tianjin Medical University Cancer Institute and Hospital

The Affiliated Hospital of Qingdao University

Jiangsu Cancer Institute & Hospital

The First Affiliated Hospital of Soochow University

Fudan University

Shanghai Pulmonary Hospital, Shanghai, China

Zhejiang Cancer Hospital

Zhejiang University

Wuhan Union Hospital, China

Tongji Hospital

West China Hospital

Tang-Du Hospital

Information provided by (Responsible Party):

Yi-Long Wu, Guangdong Association of Clinical Trials

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Actual Primary Completion Date :	March 2017
Estimated Study Completion Date :	December 2020

Publications:

Janjigian YY, Park BJ, Zakowski MF, Ladanyi M, Pao W, D'Angelo SP, Kris MG, Shen R, Zheng J, Azzoli CG. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. J Thorac Oncol. 2011 Mar;6(3):569-75. doi: 10.1097/JTO.0b013e318202bffe.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Wei YC, Liu YY, Chen C, Cheng Y, Yin R, Yang F, Ren SX, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yang JJ, Yan HH, Yang XN, Liu SY, Zhou Q, Wu YL. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. J Clin Oncol. 2021 Mar 1;39(7):713-722. doi: 10.1200/JCO.20.01820. Epub 2020 Dec 17.

Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yan HH, Yang XN, Zhou Q, Wu YL; ADJUVANT investigators. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018 Jan;19(1):139-148. doi: 10.1016/S1470-2045(17)30729-5. Epub 2017 Nov 21.

To Top